Abstract
Dysfunction of the hypothalamo-pituitary gonadal (HPG) axis may result in a variety of disorders, ranging from precocious puberty to infertility. Current therapies for such disorders have varying degrees of success, and are associated with adverse effects and / or practical limitations. The recent identification of Kisspeptin as a critical regulator of reproduction, may offer a new avenue for therapeutically manipulating the HPG axis. This article provides a synopsis of the role of Kisspeptin and the Kisspeptin receptor in reproduction, with an emphasis on potential areas of its exploitation as a therapeutic or diagnostic tool. This article also reviews some of the recent patents related to the field.
Keywords: Kisspeptin, metastin, GPR54, gonadotrophin, infertility, hypothalamus, GnRH
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery
Title: Kisspeptin: Paving the Way to a New Therapeutic Avenue in Reproduction
Volume: 3 Issue: 2
Author(s): Channa N. Jayasena, George Tharakan and Waljit S. Dhillo
Affiliation:
Keywords: Kisspeptin, metastin, GPR54, gonadotrophin, infertility, hypothalamus, GnRH
Abstract: Dysfunction of the hypothalamo-pituitary gonadal (HPG) axis may result in a variety of disorders, ranging from precocious puberty to infertility. Current therapies for such disorders have varying degrees of success, and are associated with adverse effects and / or practical limitations. The recent identification of Kisspeptin as a critical regulator of reproduction, may offer a new avenue for therapeutically manipulating the HPG axis. This article provides a synopsis of the role of Kisspeptin and the Kisspeptin receptor in reproduction, with an emphasis on potential areas of its exploitation as a therapeutic or diagnostic tool. This article also reviews some of the recent patents related to the field.
Export Options
About this article
Cite this article as:
Jayasena N. Channa, Tharakan George and Dhillo S. Waljit, Kisspeptin: Paving the Way to a New Therapeutic Avenue in Reproduction, Recent Patents on Endocrine, Metabolic & Immune Drug Discovery 2009; 3 (2) . https://dx.doi.org/10.2174/187221409788452354
DOI https://dx.doi.org/10.2174/187221409788452354 |
Print ISSN 1872-2148 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3334 |
Related Articles
-
Apoptotic and Antiproliferative Potential of GAPDH from <i>Mallotus
philippensis</i> Seed on Human Lung Carcinoma: <i>In Vitro</i> and <i>In Vivo</i>
Approach
Protein & Peptide Letters Targeting Angiogenesis in Renal Cell Carcinoma
Current Cancer Drug Targets Down-Regulation of DDR1 Induces Apoptosis and Inhibits EMT through Phosphorylation of Pyk2/MKK7 in DU-145 and Lncap-FGC Prostate Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Application of Nanomaterials in Water Treatment: Arsenic and Natural Organic Matter Removal
Recent Patents on Nanotechnology Natural Products as Anticancer Agents
Current Drug Targets Synthesis of Some Coumarinyl Chalcones and their Antiproliferative Activity Against Breast Cancer Cell Lines
Letters in Drug Design & Discovery Strategies for the Biological Evaluation of Gold Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Pharmacogenetic and Pharmacokinetic Dose Individualization of the Taxane Chemotherapeutic Drugs Paclitaxel and Docetaxel
Current Medicinal Chemistry Nicotine Replacement Therapy During Pregnancy and Lactation Induce Structural and Functional Changes in the Lungs of the Progeny
Current Women`s Health Reviews Discovery of Cationic Polymers for Non-Viral Gene Delivery Using Combinatorial Approaches
Combinatorial Chemistry & High Throughput Screening HDAC as a Therapeutic Target for Treatment of Endometrial Cancers
Current Pharmaceutical Design Pattern Recognition by CD6: A Scavenger-Like Lymphocyte Receptor
Current Drug Targets New Anti-Angiogenic Targeted Therapy in Advanced Renal Cell Carcinoma (RCC):Current Status and Future Prospects
Reviews on Recent Clinical Trials Should the Status of the Pathway Mediated by BRCA1 and BRCA2 be Evaluated Before Selecting Cancer Chemotherapy Drugs?
Current Pharmacogenomics Obesity and Arterial Compliance Alterations
Current Vascular Pharmacology Radiopharmaceutical Tracking of Particles Injected into Tumors: A Model to Study Clearance Kinetics
Current Drug Delivery Targets for Anti-metastatic Drug Development
Current Pharmaceutical Design Overview of Angiogenesis and the use of Bevacizumab in Patients with Malignant Gliomas
Current Signal Transduction Therapy Titanocenes as Anticancer Agents: Recent Insights
Medicinal Chemistry